
Accugenix Publications, Guides and
Additional Resources
Accugenix Process
AccuPRO-ID™
AccuPRO-ID IRF Page 1 of 2.pdf
AccuPRO-ID IRF Page 2 of 2.pdf
AccuPRO-ID Identification Report Guide.pdf
AccuPRO-ID Sample ID Report.pdf
Top
Accugenix Guides
Explanation of Turnaround Times (TATs).pdf
FTA Preparation Instructions.pdf
Identification Request Form Guide - Spanish.pdf
Identification Request Form Guide.pdf
International Shipment of Live Culture.pdf
Top
White Papers
White Paper - Accugenix vs MicroSeq.pdf
White Paper - Evaluating Library Databases for Microbial Identification.pdf
White Paper - ITS Fungal Method.pdf
Top
Laboratory Practice
Websites
Industry Resources
Draft guidance intended to help manufacturers meet the requirements of the US Food & Drug Administration’s current good manufacturing practice (CGMP) regulations (2l CFR parts 210 and 211) when manufacturing sterile drug and biological products using aseptic processing. This guidance, when finalized, will replace the 1987 Industry Guideline on Sterile Drug Products Produced by Aseptic Processing
16S Ribosomal DNA Sequence Analysis of a Large Collection of Environmental and Clinical Unidentifiable Bacterial Isolates From the JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2000
This article discusses the difficulty in identifying some bacterial with phenotypic identification, and the usefulness of 16S rDNA sequence analysis in the identification of conventionally unidentifiable isolates.
From the JOURNAL OF CLINICAL MICROBIOLOGY, May 2003
This article discusses use of the MicroSeq 500 16S ribosomal DNA (rDNA)-based bacterial identification system for identification of clinically significant bacterial isolates with ambiguous biochemical profiles.
From the JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2000
This article discusses evaluation of the MicroSeq sequenced-based identification system for its ability to identify clinical Mycobacterium isolates.
From the JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2003
This article discusses the MicroSeq 500 microbial identification system by nucleic acid sequencing and the Mayo Clinic experience with its integration into a routine clinical laboratory setting.
From the JOURNAL OF CLINICAL MICROBIOLOGY, May 2002
This article discusses the difficulty of identification of the species within the “Streptoccoccus milleri” group because the species share overlapping phenotypic characteristics, and the confirmation of biochemical identification with identification by 16S rRNA gene sequence analysis.
From the JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 1998
This article discusses the use of 16S rRNA gene sequencing for rapid, unambiguous identification of clinical bacterial isolates
From the JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2003
This article discusses an evaluation conducted over 18 months of use of 16S ribosomal DNA(rDNA) sequence analysis as a means of identifying aerobic gram-positive rods in the clinical laboratory. It concludes that rDNA sequencing is an effective means for the identification of aerobic gram-positive rods which are difficult to identify by conventional techniques.
From the JOURNAL OF CLINICAL MICROBIOLOGY, May 2002
This article discusses the evaluation of two automated identification systems for identification of isolates of the Burkholderia capacia complex (BCC). It reemphasizes that confirmatory identification of BCC, preferably by molecular methods, is highly recommended.
From the JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2000
This article discusses the MicroSeq 500 16S bacterial sequencing system as a potentially powerful method for the definitive identification of clinical coryneform bacterium isolates.
From the JOURNAL OF CLINICAL MICROBIOLOGY, June 1999
This article includes a discussion of use of 16S rRNA amplification and sequencing.
From the JOURNAL OF CLINICAL MICROBIOLOGY, July 2007
This article compares the performance of the VITEK 2 colorimetric card to 16S rRNA gene sequencing in the identification of 90 strains of gram-negative, nonfermentative rods. The authors found that the VITEK 2 colorimetric system identified only 53% of the isolates to the species level.